Enanta Pharmaceuticals Files 8-K on Financials
Ticker: ENTA · Form: 8-K · Filed: Feb 10, 2025 · CIK: 1177648
| Field | Detail |
|---|---|
| Company | Enanta Pharmaceuticals Inc (ENTA) |
| Form Type | 8-K |
| Filed Date | Feb 10, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
Related Tickers: ENTA
TL;DR
ENANTA FILES 8-K WITH FINANCIAL UPDATES - INVESTORS TAKE NOTE
AI Summary
Enanta Pharmaceuticals, Inc. filed an 8-K on February 10, 2025, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located at 4 Kingsbury Avenue, Watertown, Massachusetts.
Why It Matters
This 8-K filing provides an update on Enanta Pharmaceuticals' financial performance and condition, which is crucial information for investors to assess the company's health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not appear to contain any new or significant negative information.
Key Players & Entities
- Enanta Pharmaceuticals, Inc. (company) — Registrant
- February 10, 2025 (date) — Date of earliest event reported
- 4 Kingsbury Avenue, Watertown, Massachusetts 02472 (location) — Principal Executive Offices
- 001-35839 (company_id) — SEC File Number
FAQ
What specific financial information is being reported in this 8-K?
The 8-K indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was the earliest event reported in this filing?
The earliest event reported was on February 10, 2025.
What is Enanta Pharmaceuticals' principal executive office address?
The principal executive offices are located at 4 Kingsbury Avenue, Watertown, Massachusetts 02472.
What is Enanta Pharmaceuticals' SEC file number?
Enanta Pharmaceuticals' SEC file number is 001-35839.
What is the SIC code for Enanta Pharmaceuticals?
The Standard Industrial Classification (SIC) code for Enanta Pharmaceuticals is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 441 words · 2 min read · ~1 pages · Grade level 11.7 · Accepted 2025-02-10 16:05:08
Key Financial Figures
- $0.01 — ch registered Common Stock, par value $0.01 per share ENTA Nasdaq Global Select
Filing Documents
- enta-20250210.htm (8-K) — 41KB
- enta-ex99_1.htm (EX-99.1) — 208KB
- img152620751_0.jpg (GRAPHIC) — 16KB
- 0000950170-25-017035.txt ( ) — 392KB
- enta-20250210.xsd (EX-101.SCH) — 23KB
- enta-20250210_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On February 10, 2025, Enanta Pharmaceuticals, Inc. announced via press release its results for the fiscal quarter ended December 31, 2024. A copy of Enanta's press release is hereby furnished to the Commission and incorporated by reference herein as Exhibit 99.1.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit Number Description 99.1 Press Release of Enanta Pharmaceuticals, Inc. dated February 10, 2025, reporting Enanta's financial results for the fiscal quarter ended December 31, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ENANTA PHARMACEUTICALS, INC. Date: February 10, 2025 By: /s/ Paul J. Mellett Paul J. Mellett Chief Financial and Administrative Officer